Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168782 | 0.92 | HRH3 (0.70) | HRH3NPC1RAB9ACYP1A2HPGD | |
| SCHEMBL21940956 | 0.88 | HRH3 (0.70) | HRH3ACKR3ALDH1A1 | |
| SCHEMBL20147581 | 0.87 | HRH3 (0.68) | HRH3NPC1RAB9AACKR3KMT2A | |
| SCHEMBL14923986 | 0.87 | HRH3 (0.68) | HRH3LMNAALDH1A1 | |
| SCHEMBL18389994 | 0.87 | HRH3 (0.67) | HRH3NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14679122 | 0.85 | NPC1 (0.58) | HRH3NPC1RAB9ACYP1A2HPGD | |
| SCHEMBL16314580 | 0.83 | NPC1 (0.69) | NPC1RAB9ACYP1A2HPGDCYP2C19 | |
| SCHEMBL10195592 | 0.83 | NPC1 (0.69) | NPC1RAB9ACYP1A2HPGDCYP2C19 | |
| SCHEMBL241843 | 0.82 | RAB9A (0.83) | NPC1RAB9ACYP1A2HPGDCYP2C19 | |
| SCHEMBL8362540 | 0.82 | RAB9A (0.83) | NPC1RAB9ACYP1A2HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411396-A1 | TRIOXOLANE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-12-29 | — | — | US | disclosed |
| US-11072594-B2 | Trioxolane agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200140406-A1 | TRIOXOLANE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-05-07 | — | — | US | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9345719-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2016-05-24 | — | — | US | disclosed |
| US-8957065-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411396-A1 | TRIOXOLANE AGENTS | ABCB4, SLC10A1, SLC10A2 | HRH3 2136/4885NPC1 252/4885RAB9A 2056/4885 |
| US-11072594-B2 | Trioxolane agents | ABCB4, SLC10A1, SLC10A2 | HRH3 2136/4885NPC1 252/4885RAB9A 2056/4885 |
| US-20200140406-A1 | TRIOXOLANE AGENTS | ABCB4, SLC10A1, SLC10A2 | HRH3 2136/4885NPC1 252/4885RAB9A 2056/4885 |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, LTK, FYN | HRH3 1824/4885NPC1 4547/4885RAB9A 1938/4885 |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | HRH3 1748/4885NPC1 4566/4885RAB9A 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.